EF Hutton initiated coverage on Pasithea Therapeutics with a new price target
$KTTA
Biotechnology: Pharmaceutical Preparations
Health Care
EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2021 | $3.25 | Buy | EF Hutton |
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;- Dr. Tiago Reis Marques;- Prof. Larry Steinman;- Simon Dume
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022. Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and ext
SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT's) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended that the Company's Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort 5, 22mg capsule, without modification. This
-- Interim data from Cohort 4 expected Q1 2025 -- MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively recruiting patients along with the four open sites in the United States, for Pasithea's PAS-004 Phase 1 trial. In Eastern Europe, Pasithea is working with Arensia Exploratory Medicine, Institute of Oncology Bucharest, Are
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities (DLT's). In a
SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
424B5 - Pasithea Therapeutics Corp. (0001841330) (Filer)
8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
4/A - Pasithea Therapeutics Corp. (0001841330) (Issuer)
4/A - Pasithea Therapeutics Corp. (0001841330) (Issuer)
EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he
- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am